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Soluble Interleukin-6 Receptor in Patients with Severe 
Sepsis
To the Editor— We read with interest the recent study o f  Frieling 
et al. [1], which showed that patients with sepsis syndrome have 
lower circulatory concentrations o f  soluble interleukin-6 (IL-6) 
receptor (sIL-6R) and higher concentrations o f  IL-6 than do 
healthy volunteers. In addition, the study showed that serum levels 
o f  sIL-6R were not significantly different in surviving and nonsur­
viving patients.
We recently investigated serum IL-6 and sIL-6R levels at the 
time of admission to an intensive care unit and on day 4 in patients 
with severe sepsis, as defined by recent consensus definitions [2]. 
The initial severity o f  illness was assessed using the simplified 
acute physiology score (SAPS) [3]. As controls, blood samples 
were drawn from 7 healthy hospital employees. Serum levels o f  
IL-6 and sIL-6R were measured by ELISA: Detection limits were 
25 pg/mL (IL-6) and 5 ng/mL (slL-6R).
Statistical analyses were done using Student’s t test to calculate 
intergroup differences, paired Student’s t test to calculate intra­
group differences, and Pearson’s correlation to test the relationship 
between IL-6 and sIL-6R levels and SAPS scores. Results were 
expressed as mean ±  SE. P  <  .05 was considered significant.
Serum cytokine levels were measured in 18 consecutive patients 
(13 men, 5 women) with severe sepsis. Their mean age was 55 ±  
4 years (range, 22- 86), and the mean SAPS was 19.6 ±  1,2 (range, 
15-31). All but 1 patient had documented infection: gram-negative 
infections (7) and both gram-negative and -positive infections (10). 
Four patients had gram-negative bacteremia. Sources o f  infection 
were urinary ( 1), intraabdominal (7 ), and respiratory ( 10) tracts. 
Fourteen patients had septic shock and 13 had adult respiratory 
distress syndrome (8 with pneumonia); all patients were ventilated. 
B y day 28, 33% o f  the patients had died.
IL-6 was detected in all patients at study entry (range, 6 4 -  
88,300 pg/mL): The mean serum level was higher for the 6 non sur­
vivors (20,931 ±  12,789 pg/mL; range, 160-75 ,850) than for the 
12 survivors (7880 ±  7320 pg/mL; range, 181-37,650; P  — .4), 
but the difference was not statistically significant. Mean sIL-6R 
was significantly decreased in patients with severe sepsis (73 ±  7 
ng/mL; range, 17-135) compared with controls (103 ±  11 ng/ 
mL; range, 75 -166; P  — .04); however, the level in survivors (76 
± 1 0  ng/mL; range, 1 7 -1 3 5 ) was not significantly different than 
that in nonsurvivors (65 ±  9 ng/mL; range, 4 0 -9 8 ;  P  — .49). For 
individual patients, there was a significant negative correlation 
between serum levels o f IL-6 and sIL-6R at study entry (r =
— .59; P  — .009). There was also a strong correlation between 
concentrations o f  IL-6 and SAPS (r =  .73; P  =  .0005), but there 
was no correlation between levels o f  sIL-6R and SAPS.
To determine the evolution o f  serum levels o f  IL-6 and sIL-6R 
during the course o f severe sepsis, IL-6 and sIL-6R were measured 
at day 4 after study entry. The mean concentration o f sIL-6R in
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the 12 survivors increased from 76 ±  10 ng/mL at study entry to 
110 ±  17 ng/mL on day 4 (range, 5 7 -2 1 3 ;  P  =  .02). By contrast, 
the mean concentration o f  sIL-6R remained low  in the 6 nonsurvi­
vors: 65 ±  9 ng/mL at study entry and 70 ±  9 ng/mL on day 4  
(range, 4 8 -1 0 3 ;  P  — .62). As a result, mean sIL-6R on day 4 was 
significantly lower in nonsurvivors than in survivors ( P  =  .04). 
However, compared with levels at entry, concentrations o f IL-6 
on day 4 were decreased significantly in survivors (227 ±  24 ng/ 
mL; range, 2 5 -7 1 6 ;  P =  .03) but not in nonsurvivors (8205 ±  
5400 ng/mL; range, 181 -37 ,650; P  =  .13). N o correlation was 
found between levels o f IL-6 and sIL-6R at day 4.
In our study and as previously found by Frieling et al. [1], 
decreased levels o f  sIL-6R with simultaneously increased levels 
o f  IL-6 in patients with severe sepsis at study entry did not correlate 
with severity or outcome o f  illness; however, concentrations o f  
sIL-6R remained low  during the course o f  severe sepsis in patients 
who died. In patients surviving severe sepsis, concentrations o f  
sIL-6R increased to levels seen in healthy subjects. By contrast, 
the high concentrations o f  IL-6 decreased in both survivors and 
nonsurvivors. However, the decrease o f  IL-6 levels did not reach 
statistical significance in the nonsurvivor group probably due to 
the small number o f  patients involved in that study.
IL-6 levels seem be a good marker o f  the severity o f  sepsis [4] 
and are well correlated with patient outcome [5, 6]. On the other 
hand, the clinical relevance o f  sIL-6R concentrations during sepsis 
is not yet clear. sIL-6R seem s not to play an antagonist role like 
the soluble receptor for tumor necrosis factor [7] but, on the con­
trary, seems to enhance the biologic activity o f  IL-6 [8], In the 
IL-6 signaling pathway, the stimulation o f  target cells with a com ­
plex o f  sIL-6R and IL-6 induces the homodimerization o f  a non­
binding signal transducer (gp l3 0 ) and the tyrosine-specific phos­
phorylation o f  g p l3 0  [8]. The persistence o f low  levels o f  sIL-6R 
in nonsurvivors could be a host defense mechanism due to the 
severity o f  the sepsis injury. Further studies are warranted to best 
understand the role o f  sIL-6R during sepsis.
Fabrice Zeni, Bernard Tardy, Monique Vinclimian, 
Pascal Pain, Pierre Gery, and Jean-Claude Bertrand
Intensive Care Unit and Nuclear Medicine Laboratory, University
Hospital Bellevue, Saint-Étienne, France
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Reply
To the Editor— The study by Zeni et al. [1] confirms our findings 
regarding soluble interleukin-6 (IL-6) receptor (sIL-6R) concentra­
tions in patients with sepsis syndrome [2]. Their data obtained on 
day 4 after study entry provide additional information on the course 
o f  sIL-6R concentrations in such patients. The differences in con­
centrations of IL-6 and sIL-6R among survivors and nonsurvivors 
are of interest, since they are not significantly different at study 
entry but become so at day 4. This raises an interesting point and 
can be explained by the fact that IL-6 concentrations did not de­
crease at the same rate in nonsurvivors and survivors.
In a new study o f patients with meningococcal infections, we 
found that sIL-6R added to the circulation by plasma or whole 
blood exchange is cleared at a much faster rate in the presence o f  
high rather than low concentrations o f IL-6 (unpublished data). 
Because the IL-6 concentration in nonsurvivors of sepsis syndrome 
remains relatively high, the concentration o f sIL-6R will remain 
lower than normal levels. Whether the persistence o f a low concen­
tration o f  sIL-6R is a host defense mechanism or merely a result 
o f  clearance rate remains to be investigated.
Another issue of interest is that the correlation between IL-6 
and sIL-6R concentrations, which was significant at study entry, 
is not significant on day 4. This is probably due to the number o f
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Polymerase Chain Reaction for Assessing Treatment 
Response in Patients with Pulmonary Tuberculosis
To the Editor— Kennedy et a l [1] recently compared the value 
o f  stain, culture, and polymerase chain reaction (PCR) for the 
diagnosis o f pulrnonary tuberculosis using data from 10 patients; 
they suggested that PCR could be used to assess treatment response 
in these patients. Although the authors did not describe how they 
selected these 10 patients from their 200 with smear-positive tuber­
culosis, the high reliability o f PCR for sputum samples obtained 
as late as 4 months after onset of successful treatment is surprising. 
In our experience, it is extremely difficult to obtain sputum samples 
o f  good quality because patients no longer expectorate after a few
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patients with near-normal IL-6 concentrations. In patients with low  
concentrations o f  IL-6 in the previously mentioned unpublished 
study, sIL-6R concentrations exceeded the normal range before 
returning to normal These patients offset the correlation found at 
study entry.
The statement by Zeni et al. [1] that in our study [2], we found 
no relation between IL-6 and sIL-6R concentrations and severity 
o f  illness is only partly correct: We did fi nd a significant correlation 
between APACHE scores and IL-6 but not between sIL-6R and 
APACHE scores, which is in agreement with their study.
The renal function o f patients should be considered in studies 
of soluble cytokine receptors. As indicated in our study [2], moder­
ate renal impairment did not influence the concentration o f  sIL- 
6R. Subsequent to that study, however, it was shown in patients 
with severe renal insufficiency requiring renal replacement therapy 
that sIL-6R concentrations are increased, dependent on the mode 
o f  therapy (unpublished data).
We thank Zeni et al. for the additional information,
Johan T. M. Frieling, Marcel van Deuren, John Wijdenes,
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weeks o f treatment, and the number o f residual microorganisms 
in sputum must be extremely low. The detection o f  Mycobacterium  
tuberculosis by PCR in these samples suggests that this technique 
may be useful even for low-quality sputum samples that contain 
few microorganisms.
To test this hypothesis, we used a semi quantitative PCR tech­
nique with serial early morning sputum samples o f different quality 
(collected every 10 days for up to 3 months) from 5 patients with 
smear-positive pulmonary tuberculosis. Sputum specimens from 2 
healthy volunteers were used as negative controls. The quality o f  
all samples was assessed by Gram’s stain and scored as 0 to 3 + ,  
depending on the number o f  leukocytes or squamous epithelial 
cells per low-power field [2], All sputum samples were stained by 
auramine-rhodamme dye and cultured in solid medium by standard 
procedures [3]. The numbers o f acid-fast bacilli in stained smears 
were scored as 1+  to 3 + , following a standard semi quantitative 
technique [4]. For cultures, a score o f 14-, 2-1-, or 3 +  indicated 
the amount o f colonies in Lowenstein-Jensen medium (20, 2 0 -  
100, > 100 , respectively). An aliquot o f each decontaminated and 
suspended product was stored at ~20°C until processing for PCR.
PCR was done as previously described [5] with minor modifica­
tions. Briefly, the mycobacterial DNA was amplified using the Taq 
Start antibody technique (Clontech, Palo Alto, CA) to avoid cross-
